crisaborole   Click here for help

GtoPdb Ligand ID: 9151

Synonyms: AN 2728 | AN2728 | compound 5b [PMID: 19303290] | Eucrisa® | Staquis®
Approved drug Immunopharmacology Ligand
crisaborole is an approved drug (FDA (2016), EMA (2020))
Compound class: Synthetic organic
Comment: Crisaborole is a non-steroidal phosphodiesterase-4 (PDE4) inhibitor acting primarily against the PDE4B isozyme [1]. It was developed by Anacor Pharmaceuticals for its potential anti-inflammatory action in skin conditions such as psoriasis and atopic dermatitis.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 1
Rotatable bonds 2
Topological polar surface area 62.48
Molecular weight 251.08
XLogP 2.46
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES N#Cc1ccc(cc1)Oc1ccc2c(c1)COB2O
Isomeric SMILES N#Cc1ccc(cc1)Oc1ccc2c(c1)COB2O
InChI InChI=1S/C14H10BNO3/c16-8-10-1-3-12(4-2-10)19-13-5-6-14-11(7-13)9-18-15(14)17/h1-7,17H,9H2
1. Akama T, Baker SJ, Zhang YK, Hernandez V, Zhou H, Sanders V, Freund Y, Kimura R, Maples KR, Plattner JJ. (2009)
Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
Bioorg Med Chem Lett, 19 (8): 2129-32. [PMID:19303290]
2. Moustafa F, Feldman SR. (2014)
A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology.
Dermatol Online J, 20 (5): 22608. [PMID:24852768]